Seeking Alpha

Glaxo and Theravance announce positive Phase 3 results for COPD regimen

  • In two Phase 3 clinical trials, patients with chronic obstructive pulmonary disease (COPD) who received the anticholinergic Incruse Ellipta (umeclidinium 62.5 mcg) or umeclidinium 125 mcg (an unlicensed dose) in addition to Relvar/Breo Ellipta (fluticasone furoate/vilanterol "FF/VI"), an inhaled corticosteroid/long-acting beta2-agonist combination, achieved a statistically significant improvement in lung function (FEV1) compared to patients receiving FF/VI plus placebo reports GlaxoSmithKline (GSK) and commercial partner Theravance (THRX).
  • Both studies were 12-week multicenter, randomized, double-blinded placebo-controlled trials involving 1,238 patients with COPD. The primary endpoint was trough forced expiratory volume in one second (FEV1) on Day 85.
  • The full results of the studies will be posted on clinicaltrials.gov and presented at a future scientific meeting.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs